NoNO-42

Phase 3Small molecule

NNoNO Inc.

NoNO-42 is one of 55 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Ischemic StrokeActive, not recruiting

StrokePhase 3

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

NoNO-42

NNoNO Inc.

Phase 3

1 2

Savella

AbbVie

Preclinical

1 3

Proamatine

Repatha

Zantac 150

1 6

Alka-Seltzer

AAbbott

Preclinical

1 7

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Direct Anticoagulant

Bayer

Preclinical

3 9

Botulinum Toxin a

GSK

Preclinical

1 10

Antidepressant

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Ischemic Stroke

NCT06403267

Q3 2034

Phase 3Recruiting

Stroke

NCT06352632

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

Completed·NNoNO Inc.·Phase 1·NCT05636306·83 enrolled

Ischemic stroke1 trial

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

Recruiting·NNoNO Inc.·Phase 2·NCT06403267·600 enrolled

Stroke1 trial

A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)

Recruiting·TThe George Institute·Phase 3·NCT06352632·20,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NoNO-42. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NoNO-42 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NoNO-42. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NoNO Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNoNO Inc.

NoNO-42

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2034

Trials by Indication[1]

Phase 11 trial

Ischemic stroke1 trial

Stroke1 trial

References

Drug Info

Quick Facts

Related News